2005 - Memantine & Schizophrenia Google
(1)
Am J Psychiatry 162:626, March 2005
Memantine and Catatonic Schizophrenia
CHRISTOPHER THOMAS, PHARM.D., B.C.P.P.
Chillicothe, Ohio
To the Editor:
EDIT
Based upon the effectiveness shown in this patient, memantine may be a useful adjunctive therapy for schizophrenic patients with catatonic symptoms.
Message 21095526
ajp.psychiatryonline.org
(2)
Memantine, Donepezil
Kirsten Fleming, PhD
University of California, Irvine
Orange, CA
USA
2004
Steven Potkin, MD
University of California, Irvine
Orange, CA
USA
2004
Treatment Trial Grant
26 week, double-blind, placebo controlled antipsychotic
augmentation study of memantine plus donepezil in the
treatment of 60 outpatients with schizophrenia.
stanleyresearch.org
(3)
Memantine
Martin Schaefer, M.D.
Charite, Humboldt-University
Berlin
Germany
2002
Two randomized, double-blind, placebo-controlled studies of
memantine as an adjunctive treatment to risperidone in schizophrenia.
One study addresses prevention of cognitive impairment and negative symptomology in acute schizophrenia (n=40); and the
second addresses treatment of negative symptomology and
cognitive impairment in chronic schizophrenia (n=40).
stanleyresearch.org
(4)
Evaluation of the Safety and Efficacy of Memantine as
Adjunctive Treatment in Schizophrenia Patients
Phase 2 Trial
This study is currently recruiting patients.
Sponsored by: Forest Laboratories
Information provided by: Forest Laboratories
clinicaltrials.gov
John McCarthy |
